Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 13/20 | 0.52 |
| ▸ | TP53 | P04637 | 9/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917342 | 1.00 | LMNA (0.55) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4926336 | 1.00 | LMNA (0.55) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4925310 | 0.93 | LMNA (0.62) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4925319 | 0.93 | LMNA (0.62) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4925517 | 0.93 | LMNA (0.62) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4921866 | 0.91 | MAPT (0.50) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4921849 | 0.91 | MAPT (0.50) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4925278 | 0.91 | MAPT (0.50) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4915399 | 0.90 | LMNA (0.50) | LMNAMAPTTP53MAPK14NPC1 | |
| SCHEMBL4915385 | 0.90 | LMNA (0.50) | LMNAMAPTTP53MAPK14NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | claimed |
| EP-1812441-A1 | 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-08-01 | — | — | EP | claimed |
| WO-2006050946-A1 | 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-05-18 | — | — | WO | claimed |
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | MAP3K1, MAP4K2, MAP4K5 | LMNA 3959/4885MAPT 1638/4885TP53 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.